Clinical trials
Phase 2 Inflammation trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
31 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 3 |
| 2008 | 1 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 2 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 16 |
| Recruiting | 4 |
| Terminated | 4 |
| Not yet recruiting | 3 |
| Active, not recruiting | 2 |
| Withdrawn | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amgen | 2 |
| AstraZeneca | 2 |
| Montreal Heart Institute | 2 |
| British Columbia Cancer Agency | 1 |
| CHU de Quebec-Universite Laval | 1 |
| Centocor, Inc. | 1 |
| Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | 1 |
| Firestone Institute for Respiratory Health | 1 |
| Hamilton Health Sciences Corporation | 1 |
| InflaRx GmbH | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Inflammation | 31 |
| Crohn Disease | 5 |
| Central Nervous System Diseases | 2 |
| Coronary Artery Disease | 2 |
| Dementia | 2 |
| Diabetes Mellitus, Type 2 | 2 |
| Nervous System Diseases | 2 |
| Neurodegenerative Diseases | 2 |
| Obesity | 2 |
| Pain | 2 |
Trials
Showing 1 to 25 of 31. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.